Vicore Pharma (VICO.ST)

Executive Summary

Vicore Pharma is a Swedish biopharmaceutical company focused on developing innovative treatments for pulmonary and fibrotic diseases. The company's lead candidate, C21, is a first-in-class angiotensin II type 2 receptor (AT2R) agonist designed to modulate tissue repair and fibrosis. Vicore has successfully completed a Phase 2a trial (AIR) in idiopathic pulmonary fibrosis (IPF), demonstrating encouraging efficacy and safety. The company is now advancing C21 into a pivotal Phase 2b/3 program, with key data readouts expected in the near term. Vicore also leverages a digital health platform to enhance patient monitoring and clinical trial efficiency, supported by a strategic partnership with AstraZeneca. With a strong intellectual property position and a clear path to registration, Vicore represents a compelling investment opportunity in the fibrosis space. The company's recent progress includes positive feedback from regulatory authorities on its clinical development plan and expanding patent protection for C21. Vicore is well-capitalized to execute its upcoming milestones, focusing on the Phase 2b AIR II trial in IPF and exploring additional indications such as systemic sclerosis. The company's platform technology and AT2R agonist mechanism offer differentiation versus standard-of-care therapies, positioning Vicore for potential commercial success if pivotal data are positive. While inherent clinical risk remains, the upcoming catalysts provide clear value inflection points for shareholders.

Upcoming Catalysts (preview)

• Q2 2026Topline Results from Phase 2b AIR II Trial of C21 in IPF60% success
• Q3 2026FDA Orphan Drug Designation for C21 in IPF85% success
• Q4 2026Partnership Announcement for Digital Health Platform70% success